MX2023004545A - Compounds and methods for the targeted degradation of androgen receptor protein. - Google Patents

Compounds and methods for the targeted degradation of androgen receptor protein.

Info

Publication number
MX2023004545A
MX2023004545A MX2023004545A MX2023004545A MX2023004545A MX 2023004545 A MX2023004545 A MX 2023004545A MX 2023004545 A MX2023004545 A MX 2023004545A MX 2023004545 A MX2023004545 A MX 2023004545A MX 2023004545 A MX2023004545 A MX 2023004545A
Authority
MX
Mexico
Prior art keywords
compounds
target protein
androgen receptor
methods
present disclosure
Prior art date
Application number
MX2023004545A
Other languages
Spanish (es)
Inventor
Kurt Zimmermann
Hanqing Dong
Michael Berlin
Lawrence Snyder
Jing Wang
Andrew Crew
Keith Hornberger
Original Assignee
Arvinas Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations Inc filed Critical Arvinas Operations Inc
Publication of MX2023004545A publication Critical patent/MX2023004545A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Molecular Biology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Bifunctional compounds, which find utility as modulators of androgen receptor (AR), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds AR, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
MX2023004545A 2020-10-21 2021-10-20 Compounds and methods for the targeted degradation of androgen receptor protein. MX2023004545A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063094554P 2020-10-21 2020-10-21
PCT/US2021/055836 WO2022087125A1 (en) 2020-10-21 2021-10-20 Compounds and methods for the targeted degradation of androgen receptor protein

Publications (1)

Publication Number Publication Date
MX2023004545A true MX2023004545A (en) 2023-07-05

Family

ID=78820180

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004545A MX2023004545A (en) 2020-10-21 2021-10-20 Compounds and methods for the targeted degradation of androgen receptor protein.

Country Status (10)

Country Link
US (1) US20230084249A1 (en)
EP (1) EP4232445A1 (en)
JP (1) JP2023547084A (en)
KR (1) KR20230111615A (en)
CN (1) CN116783179A (en)
AU (1) AU2021365850A1 (en)
CA (1) CA3199074A1 (en)
IL (1) IL302137A (en)
MX (1) MX2023004545A (en)
WO (1) WO2022087125A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10584101B2 (en) 2016-10-11 2020-03-10 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
JP2022532342A (en) 2019-05-14 2022-07-14 ニューベイション・バイオ・インコーポレイテッド Anti-cancer nuclear hormone receptor targeting compound
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
MX2023011241A (en) 2021-03-23 2023-10-03 Nuvation Bio Inc Anti-cancer nuclear hormone receptor-targeting compounds.
EP4334314A1 (en) 2021-05-03 2024-03-13 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2023025268A1 (en) * 2021-08-27 2023-03-02 苏州晶云药物科技股份有限公司 Crystal forms of pyridazine carboxamide compound and preparation method thereof
AU2022370021A1 (en) * 2021-10-22 2024-05-09 Gluetacs Therapeutics (Shanghai) Co., Ltd. Crbn e3 ligase ligand compound, protein degrading agent developed on the basis of ligand compound, and their applications
US20240018149A1 (en) * 2022-06-30 2024-01-18 Chu-Chiang Chen Protein degradation compounds and methods of use
WO2024012570A1 (en) * 2022-07-15 2024-01-18 西藏海思科制药有限公司 Nitrogen-containing heterocyclic derivative, and composition and pharmaceutical use thereof
WO2024054952A1 (en) * 2022-09-08 2024-03-14 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP2802608A4 (en) 2012-01-12 2015-08-05 Univ Yale Compounds&methods for the enhanced degradation of targeted proteins&other polypeptides by an e3 ubiquitin ligase
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
KR20210132233A (en) 2014-04-14 2021-11-03 아비나스 오퍼레이션스, 인코포레이티드 Imide-based modulators of proteolysis and associated methods of use
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US10584101B2 (en) * 2016-10-11 2020-03-10 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor

Also Published As

Publication number Publication date
KR20230111615A (en) 2023-07-25
CA3199074A1 (en) 2022-04-28
JP2023547084A (en) 2023-11-09
CN116783179A (en) 2023-09-19
EP4232445A1 (en) 2023-08-30
IL302137A (en) 2023-06-01
US20230084249A1 (en) 2023-03-16
WO2022087125A1 (en) 2022-04-28
AU2021365850A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
MX2023004545A (en) Compounds and methods for the targeted degradation of androgen receptor protein.
PH12020500663A1 (en) Brm targeting compounds and associated methods of use
MX2022010583A (en) Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders.
MX2022011674A (en) Indazole based compounds and associated methods of use.
MX2022004526A (en) Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety.
EP4234551A3 (en) Pyridazinones as parp7 inhibitors
MX2019005007A (en) Tau-protein targeting protacs and associated methods of use.
CR20230516A (en) Modulators of bcl6 proteolysis and associated methods of use
EP4026835A3 (en) Pd-1/pd-l1 inhibitors
MX2021009563A (en) Pharmaceutical combination comprising tno155 and ribociclib.
MX2021009562A (en) Pharmaceutical combination comprising tno155 and a pd-1 inhibitor.
MX2023008031A (en) Gcn2 inhibitors and uses thereof.
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
MX2023000025A (en) Hpk1 inhibitors and uses thereof.
MY158106A (en) Inhibitors of e1 activating enzymes
WO2022031847A3 (en) Compositions and methods for inhibiting plp1 expression
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
PH12021500008A1 (en) Transglutaminase 2 (tg2) inhibitors
PH12018500423A1 (en) Inhibitors of ezh2
WO2023141570A3 (en) Compounds and methods for the targeted degradation of kras
MX2022004759A (en) Methods and compositions for treating liver diseases and disorders.
WO2022218941A3 (en) Compositions and methods for inhibiting ketohexokinase (khk)
MX2022016357A (en) Tetrazole derivatives as trpa1 inhibitors.
MX2022008627A (en) Substituted pyrazolo-pyrimidines and uses thereof.
AU2020378127A8 (en) Compounds as CD73 inhibitors